Transdermal nicotine in PD: a randomized, double-blind, placebo-controlled study

What Was Tested

Researchers studied Therapeutic nicotine (patch, non-peptide) in this randomized controlled trial publication.

An inverse association between cigarette smoking and the risk of idiopathic PD has been found in many epidemiologic studies.

The therapeutic and possible neuroprotective effects of nicotine formulations on parkinsonian symptoms are controversial.

Who Took Part

According to the abstract, 32 patients were involved.

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

After this treatment, 3 weeks without patch application followed.

The same blinded examiner assessed the patients with the Columbia University Rating Scale, the Webster scale, the Schwab-England scale, a timed walking test, with an instrumental test for fine motor skills and hand tremor, and with the Hamilton Depression Scale.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this Therapeutic nicotine (patch, non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the patients and researchers unaware of who received Therapeutic nicotine (patch, non-peptide).

A placebo (an inactive look-alike) gave the Therapeutic nicotine (patch, non-peptide) group a baseline to be compared against.

What Was Measured

The subject headings attached to it are Administration, Cutaneous, Motor Skills, Neurologic Examination, Neuroprotective Agents, Nicotine and Parkinson Disease.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide) in 32 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 3 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2001 (Neurology), a journal based in United States.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.